Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Metastatic HER2 Negative Breast Adenocarcinoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT06176261
What this trial is testing

DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs

Who this might be right for
Breast CancerBreast Cancer FemaleMetastatic Triple-Negative Breast Carcinoma+4 more
Nancy Lin, MD 58
Not applicableNot Yet RecruitingNCT07191405
What this trial is testing

Clinical Study of Chemotherapy and Immunotherapy Combined With Lactobacillus Johnsonii in Patients With Multiple Irresectable Solid Tumors

Who this might be right for
ImmunotherapyChemotherapy
Second Affiliated Hospital, Zhejiang University, School of Medicine 156
Early research (Phase 1)Study completedNCT02900664
What this trial is testing

PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)

Who this might be right for
Colorectal Cancer, Triple Negative Breast Cancer, NSCLC - Adenocarcinoma
Novartis Pharmaceuticals 283
Testing effectiveness (Phase 2)Active Not RecruitingNCT04090398
What this trial is testing

Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones

Who this might be right for
Anatomic Stage IV Breast Cancer AJCC v8Metastatic HER2-Negative Breast CarcinomaMetastatic Malignant Neoplasm in the Bone
National Cancer Institute (NCI) 70
Not applicableLooking for participantsNCT06388122
What this trial is testing

DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Breast Cancer Patients

Who this might be right for
HER2-negative Breast CancerHormone-receptor-positive Breast CancerMetastatic Breast Cancer+6 more
Mayo Clinic 100
Testing effectiveness (Phase 2)Study completedNCT02983045
What this trial is testing

A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors

Who this might be right for
MelanomaRenal Cell CarcinomaNon Small Cell Lung Cancer+4 more
Nektar Therapeutics 557
Testing effectiveness (Phase 2)Looking for participantsNCT05564377
What this trial is testing

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Who this might be right for
Advanced Malignant Solid NeoplasmAnatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8+12 more
National Cancer Institute (NCI) 2,900
Not applicableLooking for participantsNCT06805812
What this trial is testing

Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study

Who this might be right for
Breast AdenocarcinomaBreast Cancer Stage IVBreast Cancer, Metastatic+38 more
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 3,500
Testing effectiveness (Phase 2)Looking for participantsNCT06179303
What this trial is testing

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

Who this might be right for
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Locally Advanced Unresectable HER2-Negative Breast Carcinoma+3 more
University of Washington 60
Early research (Phase 1)WithdrawnNCT04498520
What this trial is testing

Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer

Who this might be right for
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8Anatomic Stage IIIB Breast Cancer AJCC v8+32 more
Pamela Munster
Early research (Phase 1)Study completedNCT03219268
What this trial is testing

MGD013 in Patients With Unresectable or Metastatic Neoplasms

Who this might be right for
Advanced Solid TumorsHematologic NeoplasmsOvarian Cancer+7 more
MacroGenics 277
Testing effectiveness (Phase 2)Looking for participantsNCT05770531
What this trial is testing

Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy

Who this might be right for
Metastatic HER2-Negative Breast CarcinomaMetastatic Triple-Negative Breast Carcinoma
Vanderbilt-Ingram Cancer Center 160
Testing effectiveness (Phase 2)Ended earlyNCT00461344
What this trial is testing

Docetaxel + Doxorubicin as Neoadjuvant Chemotherapy in Patients With Breast Cancer

Who this might be right for
Ductal Carcinoma
Sanofi 20
Testing effectiveness (Phase 2)Ended earlyNCT05554354
What this trial is testing

Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial)

Who this might be right for
Anatomic Stage IV Breast Cancer AJCC v8Metastatic HER2-Negative Breast CarcinomaMetastatic Hormone Receptor-Positive Breast Carcinoma
National Cancer Institute (NCI) 1
Testing effectiveness (Phase 2)Looking for participantsNCT06026657
What this trial is testing

Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer

Who this might be right for
Anatomic Stage IV Breast Cancer AJCC v8HER2-Negative Breast Carcinoma
Margaret Gatti-Mays 42
Testing effectiveness (Phase 2)Active Not RecruitingNCT06157892
What this trial is testing

Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors

Who this might be right for
Breast NeoplasmsGastroesophageal Junction AdenocarcinomaHER2 Low Breast Neoplasms+7 more
Seagen, a wholly owned subsidiary of Pfizer 54
Early research (Phase 1)Looking for participantsNCT05969041
What this trial is testing

Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors

Who this might be right for
Epithelial Tumors, Malignant
Myeloid Therapeutics 48
Early research (Phase 1)Looking for participantsNCT07318805
What this trial is testing

Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors

Who this might be right for
Advanced Breast CancerMetastatic Breast Cancer (HR+/ HER2-)Colorectal Cancer+2 more
Pfizer 260
Early research (Phase 1)Active Not RecruitingNCT03983954
What this trial is testing

Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.

Who this might be right for
ER+ Breast CancerOvarian CancerCervical Squamous Cell Carcinoma+17 more
NeoTX Therapeutics Ltd. 120
Testing effectiveness (Phase 2)Looking for participantsNCT06907043
What this trial is testing

PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.

Who this might be right for
Advanced Solid Tumors
Eikon Therapeutics 130
Next Page